Herpes Simplex Virus 1 (HSV1) is a prevalent lifelong virus transmitted through oral-to-oral contact resulting in painful oral sores. HSV1 may also give rise to encephalitis, or inflammation of the brain, and has even been linked to sporadic Alzheimer’s Disease (AD). Typically, HSV1 enters through the oral cavity, replicates, invades nearby clusters of sensory neurons that innervate mucosal membranes called the trigeminal ganglia, and can ultimately lead to infection of the brain. HSV1 can establish latency in these trigeminal ganglia and other neuronal nuclei, and can reactivate in the brain in response to external stresses at any point in time. Previous studies have even shown presence of HSV1 in the brain. However, this process of reactivation is still not understood. Our goal is to comprehend the mechanisms of HSV1 reactivation in the brain by generating two recombinant HSV1 through the CRISPR-Cas9 gene editing system. One strain will contain an insertion into the HSV1 genome of luciferase and mEmerald, a green fluorescent protein, for detection of cells with reactivating HSV1 through in vivo imaging of bioluminescence. The second strain will have an insertion of Cre recombinase and mEmerald. When this strain is injected into a mutant mice line with a Cre-dependent reporter gene, the Cre recombinase can lift genetic repression of a red fluorescence protein. This prompts all cells with an HSV1 infection, including those with past reactivation, to be detected. Through these novel recombinant HSV1 strains, we can monitor viral reactivation in brain cells in response to different external stresses in vivo, examine the time course of the infection, and distinguish areas of the brain with high viral load, especially cell types vulnerable to HSV1 infection. These experiments will be the stepping stone for improved investigation of viral latency and reactivation and understanding the connection between HSV1 and AD.